Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
BXQ-350 activates lysosomes therefore resulting in anti-tumor activity (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 2517-2517).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BXQ-350||SapC-DOPS||SapC-DOPS (BXQ-350) is a nanovesicle of saposin C (SapC; a lysosomal protein) and dioleylphosphatidylserine (DOPS) that targets phosphatidylserine to activate lysosomes resulting in apoptosis in cells with high surface levels of phosphatidylserine (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 2517-2517, PMID: 31918715).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||BXQ-350||Phase I||Actionable||In a Phase I trial, BXQ-350 demonstrated safety and preliminary efficacy, resulted in partial response in 6% (1/17) and stable disease in 35% (6/17) of patients with advanced solid tumors (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 2517-2517; NCT02859857).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02859857||Phase I||BXQ-350||Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors||Active, not recruiting|
|NCT04404569||Phase I||BXQ-350||Continued Treatment for Participants Enrolled in Studies of BXQ-350||Enrolling by invitation|
|NCT03967093||Phase I||BXQ-350||A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors||Active, not recruiting|